-
“Our current focus remains on tirzepatide in terms of being the best‑in‑class molecule,” said Achin Gupta, Cipla’s Managing Director and Global CEO (Designate).
-
Nuvama said housing sales value declined 6 percent year-on-year in the December quarter, the steepest fall since the upcycle began in 2021.
-
DLF reported sales bookings of Rs 419 crore during the third quarter of this fiscal.
-
Revenue during the quarter rose nearly 11 percent for Orient Electric, led by a 12.6 percent growth in the electric consumer durables segment.
-
Canara HSBC reported a 10% YoY rise in pre-tax profit for the third quarter.
-
As investors tire of crowded portfolios and average returns, concentrated equity funds are drawing attention for their clarity, conviction, and willingness to take sharper bets.
-
Bajaj Consumer Care shares surged after the company posted an 83 percent jump in consolidated net profit to Rs 46.37 crore for the December quarter of FY26.
-
Nivolumab, launched at one-fourth the price of the original drug, is one of the most widely inhibitors used in treating various cancer types including lung, melanoma, kidney and Hodgkin lymphoma
-
From January 1, investors should expect negligible sales from Revlimid, CFO MV Narasimham tells Moneycontrol. In Q3, US revenues slipped by $35 million sequentially primarily due to lower Revlimid contributions
-
The board has approved the capex budget for setting up of 120 MWp Solar Power Park in Maharashtra.
-
Aman Mehta, Managing Director of Torrent Pharma, has been appointed Managing Director of JB Pharma for a three‑year term.
-
Nifty Midcap 100 and Nifty Smallcap 100 underperformed the frontline indices, falling by up to 3 percent.
-
Private equity and strategic investors continued to chase scalable regional platforms with strong clinical depth and technology‑enabled models, EY report said.
-
A report on Monday said that Sun Pharma is evaluating a takeover of Organon & Co. in a transaction that could be valued at about $10 billion including debt, a move that would mark the biggest overseas acquisition ever by an Indian drugmaker.
-
The brokerage highlighted the company’s technology-led approach and centralised supply chain, which it said enable higher operational efficiency and more consistent product quality.
-
Polycab India reported a 36 percent year-on-year rise in consolidated profit for the third quarter, while revenue jumped 46 percent.
-
The portfolio stays firmly anchored in antibiotics, an area big pharma abandoned due to low commercial returns, with focus on products that can fight mult-drug resistant infections
-
Bharat Coking Coal IPO, the first mainboard issue of 2026, was fully subscribed within minutes of opening for bidding on January 9.
-
Silver futures for March delivery skyrocketed by Rs 13,553 to hit a record of Rs 3,01,315 per kilogram on the MCX.
-
-
Market participants attributed the decline to profit taking following indications of easing tensions in West Asia, after a moderated tone from US President Donald Trump.
-
The company said Sahay has been appointed as CEO of Birla Opus Paints and will be designated as Senior Management Personnel of the company.
-
Angel One shares rose after the company reported an 11 percent sequential increase in revenue.
-
Clinical trials showed early treatment reduced the risk of death by nearly 80 percent compared to untreated controls, with median overall survival reaching 177 months versus 17.6 months for untreated patients.
-
RedTape is seeking proposals from private equity firms Blackstone and KKR, as its founding family looks to sell a majority stake.
